drugset
drugset / Trial / NCT02387242

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

NCT02387242 ↗

Phase 1 Suspended 18 enrolled National University Hospital, Singapore
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of standard and high doses of rifampicin. Pharmacokinetics (PK) and Whole blood Bactericidal Activity (WBA) will be measured in healthy volunteers following a single dose of rifampicin at standard dose (10mg/kg) or at high dose (20mg/kg or 30mg/kg).

Timeline

Start
2015-02
Primary completion
2017-12
Completion
2017-12

Outcome

Outcome not reported

Stopped: “New relevant data published”

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampicin Small molecule 10 mg/kg Oral
Subject Rifampicin Small molecule 20 mg/kg Oral
Subject Rifampicin Small molecule 30 mg/kg Oral

Indications

tuberculosis